Evaluating Methadone as Treatment for Refractory Cancer-Induced Bone Pain.

Area of Science:

• Oncology
• Palliative Care
• Pain Management

Background:

• Cancer-induced bone pain (CIBP) significantly impacts patient quality of life.
• Traditional opioid therapies may be insufficient or associated with significant side effects for CIBP.
• Methadone is an alternative opioid with unique pharmacokinetic properties that may benefit CIBP management.

Purpose of the Study:

• To evaluate the effectiveness of methadone in managing cancer-induced bone pain (CIBP).
• To assess changes in pain scores (Numeric Rating Scale - NRS) after 28 days of methadone therapy.
• To analyze the impact of methadone on breakthrough opioid requirements (Morphine Milligram Equivalents - MME) and performance status (ECOG, PPS).

Main Methods:

• Retrospective chart review of 27 patients with CIBP receiving methadone therapy for at least 28 days.
• Pain scores (NRS) and daily breakthrough MME were recorded before and after methadone initiation.
• Eastern Cooperative Oncology Group (ECOG) and Palliative Performance Scale (PPS) scores were assessed pre- and post-methadone.

Main Results:

• Significant reduction in NRS pain scores from 7 (IQR 5-8) to 4 (IQR 4-5) (p=0.013).
• Significant decrease in daily breakthrough MME from 90 to 31 (p=0.021).
• No significant changes observed in ECOG or PPS scores (p>0.104).

Conclusions:

• Methadone is an effective option for reducing pain intensity in patients with CIBP.
• Methadone significantly decreases the requirement for breakthrough opioid medications in CIBP.
• Methadone did not significantly alter overall performance status (ECOG, PPS) in this patient cohort.